Clinica Chimica Acta: What are the SARS-CoV-2 antibody characteristics of two semi-quantitative immunoassays in emergency departments, hospitalizations, and rehabilitation patients?

!---- In the current COVID-19 pandemic, there is an urgent need for comprehensive performance assessment and clinical efficacy assessment of serological testing to understand the immune system's response to SARS-CoV-2the study measured The IgM/IgG and total antibodies against SARS-CoV-2, respectively, by cyclic enhanced fluorescence (CEFA) and microsphere immunology (MIA)independent performance evaluations include inaccuracy, repeatability, specificity, and cross-reactivity (CEFA n - 320, MIA n - 364)used these two methods to assess the clinical effectiveness of 87 first-time emergency patients, 28 inpatients (106 series samples) and 145 recovery patientsA total of 916 patients and 994 samples were assessedthe consistency of CEFA and MIA in 302 sampleswas 90.4%-94.5% (Kappa: 0.81-0.89)CEFA and MIA detected 26.2 percent and 26.3 percent SARS-CoV-2 antibodies in ED patients, respectivelyover time, the detection rate reached 100% 21 days after the onstheierthe longitudinal antibody dynamics changes measured by CEFA and MIA were well correlated and showed three types of serum transformationrecovery period serum showed a wide range of antibody levelsresults show that the rigorously validated CEFA and MIA tests are reliable for the detection of SARS-CoV-2 antibodies and show good clinical application prospects in evaluating the immune response of hospitalized and recovery patients, but it is not helpful to early screening for the first ED visit.